NPS Pharmaceuticals, Inc. (NPSP) Release: Initial Findings from PARADOX, Largest and Most Comprehensive Research Analyzing the Burden of Hypoparathyroidism, Reveals Collection of Nearly 40 Physical, Cognitive, Emotional Symptoms
6/17/2013 9:26:36 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, yesterday presented initial findings from PARADOX, which is believed to be the largest and most comprehensive collection of research to date analyzing the burden of illness for hypoparathyroidism. Findings from 374 patients in PARADOX, which NPS conducted in partnership with the Mayo Clinic and the Hypoparathyroidism Association, reveal that patients with hypoparathyroidism experience an average of 16 of the 38 physical, emotional and cognitive symptoms cited, some of which were reported for the first time in this landmark assessment. Ninety-nine percent of patients with this rare, complex endocrine disorder experience multiple symptoms despite taking medications, such as calcium and vitamin D. Further, 69% of patients with hypoparathyroidism experience serious comorbid conditions, including heart arrhythmias and kidney stones. The findings were presented at ENDO 2013, The Endocrine Society’s 95th Annual Meeting in San Francisco, CA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by